Shah, A. N., Flaum, L., Helenowski, I., Santa-Maria, C. A., Jain, S., Rademaker, A., . . . Gradishar, W. Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer. BMJ Publishing Group.
Chicago Style (17th ed.) CitationShah, Ami N., et al. Phase II Study of Pembrolizumab and Capecitabine for Triple Negative and Hormone Receptor-positive, HER2−negative Endocrine-refractory Metastatic Breast Cancer. BMJ Publishing Group.
MLA (9th ed.) CitationShah, Ami N., et al. Phase II Study of Pembrolizumab and Capecitabine for Triple Negative and Hormone Receptor-positive, HER2−negative Endocrine-refractory Metastatic Breast Cancer. BMJ Publishing Group.
Warning: These citations may not always be 100% accurate.